Remarkably, EGCG and quercetin have shown to sensitize prostate-cancer cells to Docetaxel and Enzalutamide, among others, by improving their anti-proliferative effect and by inhibiting androgen receptor signaling [67,68]. This evidence concerns the gene AR and prostate carcinoma.